Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, China.
CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica (SIMM), Shanghai, 201203, China.
Acta Pharmacol Sin. 2020 Apr;41(4):471-482. doi: 10.1038/s41401-020-0365-y. Epub 2020 Feb 28.
Parkinson's disease (PD) is the second most common progressive neurodegenerative disease worldwide. However, there is no available therapy reversing the neurodegenerative process of PD. Based on the loss of dopamine or dopaminergic dysfunction in PD patients, most of the current therapies focus on symptomatic relief to improve patient quality of life. As dopamine replacement treatment remains the most effective symptomatic pharmacotherapy for PD, herein we provide an overview of the current pharmacotherapies, summarize the clinical development status of novel dopaminergic agents, and highlight the challenge and opportunity of emerging preclinical dopaminergic approaches aimed at managing the features and progression of PD.
帕金森病（PD）是全球第二常见的进行性神经退行性疾病。然而，目前尚无能够逆转 PD 神经退行性过程的治疗方法。基于 PD 患者中多巴胺的丧失或多巴胺能功能障碍，大多数当前的治疗方法侧重于症状缓解，以改善患者的生活质量。由于多巴胺替代治疗仍然是 PD 最有效的对症药物治疗，因此，本文综述了当前的药物治疗方法，总结了新型多巴胺能药物的临床开发状况，并强调了新兴的临床前多巴胺能方法在管理 PD 的特征和进展方面所面临的挑战和机遇。
